

Sustainability Accounting Standards Board (SASB) index 2024

The Novartis SASB index aligns with the Biotechnology & Pharmaceuticals Sustainability Accounting Standard (industry standard | version 2023-12). Data and information referenced are sourced from the Novartis 2024 annual reporting suite (Novartis in Society Integrated Report and Annual Report/Form 20-F), our corporate website, Novartis public policies and positions, and public databases or selected materials from third parties where applicable.

SASB indicator		Reference
Safety of Clinical Trial Participants		
HC-BP-210a.1	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	p. 38-39 Novartis Commitment to Patients and Caregivers Human Rights Commitment Statement Ethics in Clinical Trials
HC-BP-210a.2	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	p. 39 ESG Index: Quality
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	All significant legal proceedings are disclosed within the Annual Report and accounts (Annual Report).
Access to Medicines		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	p. 40-41 Access to Medicines Index
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Novartis has malaria products on the WHO List of Prequalified Medicinal Products.
Affordability & Pricing		
HC-BP-240b.2	Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	not reported
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	not reported
Drug Safety		
HC-BP-250a.1	Products listed in any public medical product safety or adverse event alert database	Available via FDA Adverse Event Reporting website
HC-BP-250a.2	Number of fatalities associated with products	Available via FDA Adverse Event Reporting website
HC-BP-250a.3	(1) Number of recalls issued, (2) total units recalled	p. 39
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	p. 39
HC-BP-250a.5	Number of enforcement actions taken in response to violations of Good Manufacturing Practices (GMP) or equivalent standards, by type	ESG Index: Quality

SASB indicator		Reference
Counterfeit Drugs		
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	p. 39 Novartis Position on Falsified Medical Products
HC-BP-260a.2	Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	p. 39
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	p. 39
Ethical Marketing		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Annual Report
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	p. 42 Code of Ethics Doing Business Ethically policy
Employee Recruitment, Development & Retention		
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	p. 34 Careers Research & Development US Biomedical Research Internship Programs
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	p. 60
Supply Chain Management		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	p. 46 Novartis Quality Management System (QMS) External Partner Risk Management (EPRM)
Business Ethics		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Annual Report
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	p. 42 Code of Ethics Doing Business Ethically policy
Activity Metrics		
HC-BP-000.A	Number of patients treated	p. 40
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	(1) Novartis products (2) p. 22-23